These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

959 related items for PubMed ID: 33941192

  • 1. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS.
    Cardiovasc Diabetol; 2021 Apr 30; 20(1):94. PubMed ID: 33941192
    [Abstract] [Full Text] [Related]

  • 2. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S.
    Cardiovasc Diabetol; 2020 Feb 08; 19(1):14. PubMed ID: 32035487
    [Abstract] [Full Text] [Related]

  • 3. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.
    Cardiovasc Diabetol; 2019 Nov 09; 18(1):149. PubMed ID: 31706300
    [Abstract] [Full Text] [Related]

  • 4. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
    Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M.
    J Am Heart Assoc; 2020 Mar 03; 9(5):e014129. PubMed ID: 32114889
    [Abstract] [Full Text] [Related]

  • 5. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 03; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 6. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial.
    Lorenzatti AJ, Eliaschewitz FG, Chen Y, Lu J, Baass A, Monsalvo ML, Wang N, Hamer AW, Ge J.
    Diabetes Obes Metab; 2019 Jun 03; 21(6):1455-1463. PubMed ID: 30821053
    [Abstract] [Full Text] [Related]

  • 7. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb 03; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 8. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
    Li T, Zhang Y, Cong H.
    BMC Cardiovasc Disord; 2021 Jan 07; 21(1):19. PubMed ID: 33413096
    [Abstract] [Full Text] [Related]

  • 9. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.
    Chen Y, Yuan Z, Lu J, Eliaschewitz FG, Lorenzatti AJ, Monsalvo ML, Wang N, Hamer AW, Ge J.
    Diabetes Obes Metab; 2019 Jun 07; 21(6):1464-1473. PubMed ID: 30851062
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
    Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P.
    Diabetologia; 2019 Jun 07; 62(6):948-958. PubMed ID: 30953107
    [Abstract] [Full Text] [Related]

  • 11. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.
    Lorenzatti AJ, Eliaschewitz FG, Chen Y, Fialkow J, Lu J, Baass A, Monsalvo ML, Hsu HC, Somaratne R, Ge J.
    Clin Cardiol; 2018 Sep 07; 41(9):1117-1122. PubMed ID: 29962050
    [Abstract] [Full Text] [Related]

  • 12. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F, Kumar PN, Caramelli B, Calmy A, López JAG, Bray S, Cyrille M, Rosenson RS, BEIJERINCK Investigators.
    J Am Coll Cardiol; 2020 May 26; 75(20):2570-2584. PubMed ID: 32234462
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, Letierce A, Thompson D, Colhoun HM.
    Atherosclerosis; 2018 Sep 26; 276():124-130. PubMed ID: 30059843
    [Abstract] [Full Text] [Related]

  • 15. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Sep 26; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 16. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2015 Dec 26; 35(12):2686-93. PubMed ID: 26515419
    [Abstract] [Full Text] [Related]

  • 17. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
    Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP.
    J Cardiovasc Pharmacol Ther; 2018 Sep 26; 23(5):423-432. PubMed ID: 29768954
    [Abstract] [Full Text] [Related]

  • 18. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 26; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 19. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.
    Cardiovasc Diabetol; 2017 May 25; 16(1):70. PubMed ID: 28545518
    [Abstract] [Full Text] [Related]

  • 20. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.
    J Am Heart Assoc; 2017 Oct 02; 6(10):. PubMed ID: 28971955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.